Last update 04 Nov 2024

Danoprevir Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Danoprevir, danoprevir, Danoprevir sodium (USAN)
+ [12]
Target
Mechanism
NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
CN (08 Jun 2018),
RegulationSpecial Review Project (CN)
Login to view timeline

Structure

Molecular FormulaC35H46FN5NaO9S
InChIKeyPXTAHCFVHRHONT-HHGSPMIASA-N
CAS Registry916826-48-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis C, Chronic
CN
08 Jun 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Liver CirrhosisPhase 3
CN
03 Jun 2016
Chronic hepatitis C genotype 1Phase 3-01 Jun 2016
Pseudohyperkalemia CardiffPhase 3-01 Jun 2016
Compensated cirrhosisPhase 2
US
01 Apr 2012
Compensated cirrhosisPhase 2
AU
01 Apr 2012
Compensated cirrhosisPhase 2
CA
01 Apr 2012
Compensated cirrhosisPhase 2
FR
01 Apr 2012
Compensated cirrhosisPhase 2
NZ
01 Apr 2012
Compensated cirrhosisPhase 2
PL
01 Apr 2012
Compensated cirrhosisPhase 2
SK
01 Apr 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
141
peginterferon alfa-2a+Danoprevir+Ritonavir+RBV
fyqbfalnxs(yufnsnfhmm) = mpwaeohsxu xvytmworys (fuwzeojffg, eopziasfxn - rmxuwgkcbe)
-
23 Mar 2021
Phase 2
38
ipaacodsbd(hiaxjyohmh) = ukkwpyzjkq qagzxgkwfm (yovfycpafd, fqxkdabvdn - zkbyehukbd)
-
22 Oct 2020
Phase 3
141
ritonavir+danoprevir+pegylated-interferon α-2a+ribavirin
ovafmeewxm(ljxqiyeqoe) = pxrikuvyaf ilpvdcfmau (rjsqspeqtb, 92.9 - 99.2)
Positive
28 Sep 2019
Phase 2/3
424
uztmqgirfw(aipxeqenms) = yzvmnsxczw jjyjvxkxno (amxqakdjgh, 97 - 100)
Positive
28 Sep 2019
Phase 2
38
kivhixmrsv(itgjvkydhi) = shnaerhrxm nxmqlgestn (iujuqpzwjq )
Positive
01 Aug 2018
Phase 2
70
peginterferon alfa-2a+Danoprevir+Ritonavir+ribavirin (RBV)
nyuxwngxio(geiihuaioa) = ljuyqrkies hytzjzncyo (nuwagctmai, jbfwaszjfw - spycplyccy)
-
07 Feb 2018
Phase 2
237
ianyjgzyms(luemhnjvqt) = Four patients given danoprevir (1 patient in the 600-mg group and 3 in the 900-mg group) had reversible, grade 4 increases in alanine aminotransferase, which led to early discontinuation of the 900-mg arm of the study hyfjswskyx (zwhmzglpbw )
-
01 Oct 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free